| wang, Huaqing |
| Recruiting | 3 | 400 | RoW | Tonifying Spleen and Kidney Sequential Regimen, TSKSR, Placebo of 'Tonifying Spleen and Kidney Sequential Regimen, Placebo of TSKSR | Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing University of Chinese Medicine, Peking University Third Hospital, Beijing Chao Yang Hospital, Jiangsu Province Hospital of Traditional Chinese Medicine, Shanghai Zhongshan Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, Tianjin Union Medical Center, Henan Provincial People's Hospital, Zhengzhou Hospital of Traditional Chinese Medicine, Peking University Cancer Hospital & Institute, Chongqing University Cancer Hospital, Civil Aviation General Hospital | Colon Cancer | 05/21 | 05/21 | | |
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
|
|
| Recruiting | 3 | 711 | Europe, Canada, Japan, US, RoW | Dostarlimab, CAPEOX, FOLFOX | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | 12/28 | 12/30 | | |
NCT04324879: A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL) |
|
|
| Recruiting | 2 | 80 | RoW | TQ-B3525 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Relapsed / Refractory Follicular Lymphoma | 12/22 | 12/22 | | |
TQB3702-II-02, NCT06566586: A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma |
|
|
| Recruiting | 2 | 80 | RoW | TQB3702 tablets+Chemotherapy regimen | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | B-cell Lymphoma | 03/26 | 12/27 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
NCT03510767: A Study of TQ-B3525 on Tolerance and Pharmacokinetics |
|
|
| Recruiting | 1 | 60 | RoW | TQ-B3525 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Relapsed or Refractory Lymphoma or Advanced Cancer | 08/22 | 08/24 | | |
NCT03692663: Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer |
|
|
| Recruiting | 1 | 9 | RoW | TABP EIC, Cyclophosphamide, fludarabine | Allife Medical Science and Technology Co., Ltd., Tianjin People's Hospital | Metastatic Castration-resistant Prostate Cancer | 06/23 | 06/24 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
